guidelines:
  1: UCSF_CAPRA_Assessment.v1
test_cases:
- id: case_1:Very low risk 
  input:
    1:
      gt0006|Total score: 0
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 0|local::at0021|99.3%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 0|local::at0025|97.5%|
      gt0034|Managment: 0|local::at0011|Consider routine surveillance.|
      gt0035|Risk level: 0|local::at0015|Very low risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 0|local::at0041|92.5%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 0|local::at0029|99.7%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 0|local::at0038|97.1%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 0|local::at0035|71.4%|

- id: case_2:Low risk 
  input:
    1:
      gt0006|Total score: 1
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 0|local::at0021|99.3%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 0|local::at0025|97.5%|
      gt0034|Managment: 1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|
      gt0035|Risk level: 1|local::at0016|Low risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 0|local::at0041|92.5%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 0|local::at0029|99.7%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 0|local::at0038|97.1%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 0|local::at0035|71.4%|

- id: case_3:Intermediate risk 
  input:
    1:
      gt0006|Total score: 3
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 1|local::at0022|96.9%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 1|local::at0026|93.3%|
      gt0034|Managment: 1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|
      gt0035|Risk level: 2|local::at0017|Intermediate risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 1|local::at0042|90.2%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 1|local::at0030|98.6%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 1|local::at0039|91.6%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 1|local::at0036|59.7%|

- id: case_4:Intermediate risk 
  input:
    1:
      gt0006|Total score: 4
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 1|local::at0022|96.9%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 1|local::at0026|93.3%|
      gt0034|Managment: 2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|
      gt0035|Risk level: 2|local::at0017|Intermediate risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 1|local::at0042|90.2%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 1|local::at0030|98.6%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 1|local::at0039|91.6%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 1|local::at0036|59.7%|

- id: case_5:High risk 
  input:
    1:
      gt0006|Total score: 6
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 2|local::at0023|90.4%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 2|local::at0027|83.4%|
      gt0034|Managment: 2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|
      gt0035|Risk level: 3|local::at0018|High risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 2|local::at0043|78.7%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 2|local::at0031|93.4%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 2|local::at0040|79.1%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 2|local::at0037|42.0%|


- id: case_6:Very high risk 
  input:
    1:
      gt0006|Total score: 7
      gt0042|Event time: 2019-06-18T15:04Z
  expected_output:
    1:
      'gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood': 2|local::at0023|90.4%|
      'gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood': 2|local::at0027|83.4%|
      gt0034|Managment: 3|local::at0044|Consider either multimodal therapy OR hormonal therapy|
      gt0035|Risk level: 4|local::at0019|Very High risk|
      'gt0038|Score interpretation: 5 Year Overall survival % likelihood': 2|local::at0043|78.7%|
      'gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 2|local::at0031|93.4%|
      'gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 2|local::at0040|79.1%|
      'gt0041|Score interpretation: 10 Year Overall survival % likelihood': 2|local::at0037|42.0%|


